| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.brookslabs.net | |
| Market Cap | 258.89 Cr. | |
| Enterprise Value(EV) | 280.35 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -8.82 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.54 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 32.47 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 3.26 | Calculated using Price: 105.85 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 2.47 Cr. | 24,702,812 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production. | ||
| 1 Day |
|
+4.65% |
| 1 Week |
|
+2.57% |
| 1 Month |
|
-3.20% |
| 3 Month |
|
+0.81% |
| 6 Month |
|
+26.01% |
| 1 Year |
|
+8.73% |
| 2 Year |
|
+69.77% |
| 5 Year |
|
+23.15% |
| 10 Year |
|
+589.58% |
| 2 years | 2021-03 | 2022-03 | |
| Return on Equity (%) | -24.48 | -27.16 | |
| Return on Capital Employed (%) | -5.33 | -21.03 | |
| Return on Assets (%) | -11.95 | -10.83 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 79 | 63 | 80 | |
| Non Curr. Liab. | 19 | 11 | 4 | |
| Curr. Liab. | 64 | 49 | 60 | |
| Minority Int. | 71 | 59 | ||
| Equity & Liab. | 162 | 195 | 203 | |
| Non Curr. Assets | 112 | 133 | 149 | |
| Curr. Assets | 47 | 61 | 54 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 162 | 195 | 203 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 77 | 91 | 83 | |
| Other Income | 1 | 1 | 1 | |
| Total Income | 78 | 92 | 83 | |
| Total Expenditure | -77 | -105 | -111 | |
| PBIDT | 1 | -13 | -27 | |
| Interest | -3 | -3 | -3 | |
| Depreciation | -7 | -7 | -8 | |
| Taxation | -10 | 5 | 7 | |
| Exceptional Items | ||||
| PAT | -19 | -19 | -31 | |
| Minority Interest | 3 | 9 | ||
| Share Associate | 0 | |||
| Other Related Items | ||||
| Consolidated Net Profit | -19 | -16 | -22 | |
| Adjusted EPS | -8 | -7 | -9 |
| Particulars | 2 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | -37 | |
| Cash Fr. Inv. | -5 | -25 | |
| Cash Fr. Finan. | 1 | 64 | |
| Net Change | 0 | 2 | |
| Cash & Cash Eqvt | 1 | 3 |
|
Tue, 31 Jan 2023
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Notice of Postal Ballot |
|
Fri, 27 Jan 2023
Board Meeting Outcome for Revised Outcome Of Board Meeting Dated 25Th January 2023 Revised outcome of Board meeting dated 25th January 2023 |
|
Wed, 25 Jan 2023
Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Rights Issue And Postal Ballot Notice outcome of Board Meeting for approval of Rights Issue and Postal Ballot Notice |
| Tue, 31 Jan 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Opening at Low
|
Closing Above Previous High
|
Equities
M.F.
Sectors